# version-2
rn	0	0	1
rn	1	1	2
rn	2	2	3
rn	3	3	4
rn	4	4	5
rn	5	5	6
rn	6	6	7
rn	7	7	8
rn	8	8	9
rn	9	9	10
rn	19	19	11
rn	20	20	12
rn	21	21	13
cnt	Ethiopia	Ethiopia	1
cnt	Tanzania	Tanzania	2
cnt	Uganda	Uganda	3
sf	1984	1984	1
sf	1992	1992	2
sf	1995	1995	3
sf	1998	1998	4
sf	1999	1999	5
sf	2002	2002	6
sf	2003	2003	7
sf	2004	2004	8
sf	2005	2005	9
sf	2006	2006	10
sf	2007	2007	11
sf	2008	2008	12
sf	2009	2009	13
sf	2010	2010	14
sf	2011	2011	15
sf	2012	2012	16
sf	2013	2013	17
sf	2014	2014	18
sf	2015	2015	19
sto	1994	1994	20
sto	1998	1998	21
sto	1999	1999	22
sto	2002	2002	23
sto	2003	2003	24
sto	2004	2004	25
sto	2005	2005	26
sto	2006	2006	27
sto	2007	2007	28
sto	2008	2008	29
sto	2009	2009	30
sto	2010	2010	31
sto	2011	2011	32
sto	2012	2012	33
sto	2013	2013	34
sto	2014	2014	35
sto	2015	2015	36
mt	pfcrt 76K/T	pfcrt 76K/T	1
mt	pfcrt 76T	pfcrt 76T	2
mt	pfcrt CIET	pfcrt CIET	3
mt	pfcrt CMET	pfcrt CMET	4
mt	pfcrt CMNK	pfcrt CMNK	5
mt	pfcrt CMNT	pfcrt CMNT	6
mt	pfcrt K76	pfcrt K76	7
mt	pfcrt SMNT	pfcrt SMNT	8
mt	pfmdr1 1246D/Y	pfmdr1 1246D/Y	9
mt	pfmdr1 1246Y	pfmdr1 1246Y	10
mt	pfmdr1 184F	pfmdr1 184F	11
mt	pfmdr1 184Y/F	pfmdr1 184Y/F	12
mt	pfmdr1 86N/Y	pfmdr1 86N/Y	13
mt	pfmdr1 86Y	pfmdr1 86Y	14
mt	pfmdr1 D1246	pfmdr1 D1246	15
mt	pfmdr1 N1042	pfmdr1 N1042	16
mt	pfmdr1 N86	pfmdr1 N86	17
mt	pfmdr1 NFD	pfmdr1 NFD	18
mt	pfmdr1 S1034	pfmdr1 S1034	19
mt	pfmdr1 Y184	pfmdr1 Y184	20
mt	pfmdr1 YYY	pfmdr1 YYY	21
mt	pfmdr1 copy number >1	pfmdr1 copy number >1	22
pyear	2001		1
pyear	2002		2
pyear	2006		3
pyear	2007		4
pyear	2008		5
pyear	2009		6
pyear	2010		7
pyear	2011		8
pyear	2012		9
pyear	2013		10
pyear	2014		11
pyear	2015		12
pyear	2016		13
pyear	2017		14
pyear	NULL	:::UNDEF:::	15
dru	Amodiaquine		1
dru	Lumefantrine		2
dru	Mefloquine		3
mgr	pfcrt 72-76 CxxxK	pfcrt 72-76 CxxxK	1
mgr	pfcrt 72-76 CxxxT	pfcrt 72-76 CxxxT	2
mgr	pfcrt 72-76 SxxxT	pfcrt 72-76 SxxxT	3
mgr	pfcrt 76K/T	pfcrt 76K/T	4
mgr	pfcrt 76T	pfcrt 76T	5
mgr	pfcrt K76	pfcrt K76	6
mgr	pfmdr1 1246D/Y	pfmdr1 1246D/Y	7
mgr	pfmdr1 1246Y	pfmdr1 1246Y	8
mgr	pfmdr1 184F	pfmdr1 184F	9
mgr	pfmdr1 184Y/F	pfmdr1 184Y/F	10
mgr	pfmdr1 86N/Y	pfmdr1 86N/Y	11
mgr	pfmdr1 86Y	pfmdr1 86Y	12
mgr	pfmdr1 D1246	pfmdr1 D1246	13
mgr	pfmdr1 N1042	pfmdr1 N1042	14
mgr	pfmdr1 N86	pfmdr1 N86	15
mgr	pfmdr1 NFD	pfmdr1 NFD	16
mgr	pfmdr1 S1034	pfmdr1 S1034	17
mgr	pfmdr1 Y184	pfmdr1 Y184	18
mgr	pfmdr1 YYY	pfmdr1 YYY	19
mgr	pfmdr1 copy number >1	pfmdr1 copy number >1	20
iore	E	Excluded	1
iore	I	Included	2
iore	NULL	:::UNDEF:::	
sna	Dilla	Dilla	1
sna	Jimma	Jimma	2
sna	Shalla district	Shalla district	3
sna	Omo Nada, Bala Wajo, Arba Minch, Harar	Omo Nada, Bala Wajo, Arba Minch, Harar	4
sna	Adis Ababa	Adis Ababa	5
sna	Dodoma	Dodoma	6
sna	Bagamoyo District	Bagamoyo District	7
sna	Masasi	Masasi	8
sna		:::UNDEF:::	9
sna	Iringa	Iringa	10
sna	Mkokola	Mkokola	11
sna	Kwamasimba	Kwamasimba	12
sna	Muheza	Muheza	13
sna	Mbeya, Matema	Mbeya, Matema	14
sna	Fukayosi	Fukayosi	15
sna	Mkokola, Kwamasimba	Mkokola, Kwamasimba	16
sna	Kaporo	Kaporo	17
sna	Kibaha District	Kibaha District	18
sna	Mwanza	Mwanza	19
sna	Korogwe	Korogwe	20
sna	Igombe health centre	Igombe health centre	21
sna	Mwanza (Misungwi district)	Mwanza (Misungwi district)	22
sna	Kagera (Muleba district)	Kagera (Muleba district)	23
sna	Tanga (Bondo village)	Tanga (Bondo village)	24
sna	Mtwara (Tandahimba and Mtwara-Urban)	Mtwara (Tandahimba and Mtwara-Urban)	25
sna	Coastal Region (Kibiti-Rufiji)	Coastal Region (Kibiti-Rufiji)	26
sna	Mbeya (Kyela and Rungwe districts)	Mbeya (Kyela and Rungwe districts)	27
sna	Tanga	Tanga	28
sna	Coastal, Kibiti	Coastal, Kibiti	29
sna	Mtwara	Mtwara	30
sna	Mbeya	Mbeya	31
sna	Kagera	Kagera	32
sna	Mkuzi	Mkuzi	33
sna	Kampala	Kampala	34
sna	Gulu	Gulu	35
sna	Tororo	Tororo	36
sna	Jinja	Jinja	37
sna	Kanungu	Kanungu	38
sna	Apac	Apac	39
sna	Rukungiri	Rukungiri	40
sna	Kabarole	Kabarole	41
sna	Arua	Arua	42
sna	Mubende	Mubende	43
sna	Kampala, Kakira	Kampala, Kakira	44
sna	Iganga	Iganga	45
sna	Kampala Wakiso	Kampala Wakiso	46
sna	Apac, Mubende, Kanungu	Apac, Mubende, Kanungu	47
tit	High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.	High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia	1
tit	Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia.	Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia	2
tit	High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia	High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia	3
tit	Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia.	Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia	4
tit	NULL	:::UNDEF:::	5
tit	Molecular mutation profile of pfcrt in Plasmodium falciparum isolates imported from Africa in Henan province.	Molecular mutation profile of pfcrt in Plasmodium falciparum isolates imported from Africa in Henan province	6
tit	Adding a single low-dose of primaquine (0.25å mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial.	Adding a single low-dose of primaquine (0.25å mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial	7
tit	A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by Chloroquine treatment in Tanzania.	A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by Chloroquine treatment in Tanzania	8
tit	Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa.	Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa	9
tit	Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania.	Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania	10
tit	[Molecular epidemiology of imported malaria in Italy: the use of genetic markers and in vitro sensitivity test in a study of chloroquine resistance in Plasmodium falciparum].	Molecular epidemiology of imported malaria in Italy: the use of genetic markers and in vitro sensitivity test in a study of chloroquine resistance in Plasmodium falciparum	11
tit	Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.	Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria	12
tit	Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.	Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania	13
tit	Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa.	Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa	14
tit	The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa.	The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa	15
tit	In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.	In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa	16
tit	Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene.	Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene	17
tit	Low level genotypic chloroquine resistance near Malawi's northern border with Tanzania.	Low level genotypic chloroquine resistance near Malawi's northern border with Tanzania	18
tit	Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study.	Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study	19
tit	Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial.	Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial	20
tit	Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine?	Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine	21
tit	Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy.	Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy	22
tit	Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samples.	Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samples	23
tit	Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania.	Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania	24
tit	Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.	Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania	25
tit	Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania.	Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania	26
tit	Single nucleotide polymorphisms in Plasmodium falciparum V type H(+) pyrophosphatase gene (pfvp2) and their associations with pfcrt and pfmdr1 polymorphisms.	Single nucleotide polymorphisms in Plasmodium falciparum V type H(+) pyrophosphatase gene (pfvp2) and their associations with pfcrt and pfmdr1 polymorphisms	27
tit	Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania.	Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania	28
tit	Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.	Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy	29
tit	Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania.	Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania	30
tit	Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.	Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda	31
tit	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity.	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity	32
tit	Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.	Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda	33
tit	Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala	Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala	34
tit	The Lys-76-Thr mutation in PfCRT and chloroquine resistance in Plasmodium falciparum isolates from Uganda.	The Lys-76-Thr mutation in PfCRT and chloroquine resistance in Plasmodium falciparum isolates from Uganda	35
tit	Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance.	Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance	36
tit	Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results?	Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results	37
tit	Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.	Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance	38
tit	Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic.	Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic	39
tit	Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.	Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda	40
tit	Real-time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India.	Real-time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India	41
tit	Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum.	Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum	42
tit	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda	43
tit	Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.	Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda	44
tit	Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.	Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda	45
tit	Detection of copy number variation and single nucleotide polymorphisms in genes involved in drug resistance and other phenotypic traits in P. falciparum clinical isolates collected from Uganda.	Detection of copy number variation and single nucleotide polymorphisms in genes involved in drug resistance and other phenotypic traits in P. falciparum clinical isolates collected from Uganda	46
tit	Differential Prevalence of Transporter Polymorphisms in Symptomatic and Asymptomatic Falciparum Malaria Infections in Uganda.	Differential Prevalence of Transporter Polymorphisms in Symptomatic and Asymptomatic Falciparum Malaria Infections in Uganda	47
tit	Comparative Impacts Over 5 Years of Artemisinin-Based Combination Therapies on Plasmodium falciparum Polymorphisms That Modulate Drug Sensitivity in Ugandan Children.	Comparative Impacts Over 5 Years of Artemisinin-Based Combination Therapies on Plasmodium falciparum Polymorphisms That Modulate Drug Sensitivity in Ugandan Children	48
tit	Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda.	Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda	49
tit	Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda.	Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda	50
tit	Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.	Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults	51
tit	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial	52
aut	Schunk M	Schunk M	1
aut	Eshetu T	Eshetu T	2
aut	Golassa L	Golassa L	3
aut	Kebede S	Kebede S	4
aut	NULL	NULL	5
aut	Zhou RM, Zhang HW, Yang CY, Liu Y, Zhao YL, Li SH, Qian D, Xu BL	Zhou RM, Zhang HW, Yang CY, Liu Y, Zhao YL, Li SH, Qian D, Xu BL	6
aut	Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, Mmbando B, BjÌ¦rkman A, MÌ´rtensson A	Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, Mmbando B, BjšrkmanÊ A, MŒrtensson A	7
aut	Schneider AG	Schneider AG	8
aut	Severini C	Severini C	9
aut	Alifrangis M	Alifrangis M	10
aut	Menegon M	Menegon M	11
aut	Humphreys GS	Humphreys GS	12
aut	SchÌ¦nfeld M	Schšnfeld M	13
aut	Holmgren G	Holmgren G	14
aut	Sisowath C	Sisowath C	15
aut	Bridges DJ	Bridges DJ	16
aut	Ngasala B	Ngasala B	17
aut	Ngasala BE	Ngasala BE	18
aut	Kamugisha E	Kamugisha E	19
aut	Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M	Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M	20
aut	Saito-Nakano Y	Saito-Nakano Y	21
aut	Malmberg M	Malmberg M	22
aut	Mohammed A	Mohammed A	23
aut	Jovel IT	Jovel IT	24
aut	Kavishe RA	Kavishe RA	25
aut	Gadalla N	Gadalla N	26
aut	Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, Tachibana SI, Auma M, Ntege EH, Ito D, Takashima E, Palacpac NM, Egwang TG, Onen JO, Kataoka M, Kimura E, Horii T, Tsuboi T	Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, Tachibana SI, Auma M, Ntege EH, Ito D, Takashima E, Palacpac NM, Egwang TG, Onen JO, Kataoka M, Kimura E, Horii T, Tsuboi T	27
aut	Nankabirwa JI, Conrad MD, Legac J, Tukwasibwe S, Tumwebaze P, Wandera B, Brooker SJ, Staedke SG, Kamya MR, Nsobya SL, Dorsey G, Rosenthal PJ	Nankabirwa JI, Conrad MD, Legac J, Tukwasibwe S, Tumwebaze P, Wandera B, Brooker SJ, Staedke SG, Kamya MR, Nsobya SL, Dorsey G, Rosenthal PJ	28
aut	Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B, Nsobya SL, Kamya MR, Dorsey G, Rosenthal PJ	Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B, Nsobya SL, Kamya MR, Dorsey G, Rosenthal PJ	29
aut	Dorsey G	Dorsey G	30
aut	Kyosiimire-Lugemwa J	Kyosiimire-Lugemwa J	31
aut	Talisuna A	Talisuna A	32
aut	Francis D	Francis D	33
aut	Dokomajilar C	Dokomajilar C	34
aut	Nsobya SL	Nsobya SL	35
aut	Keen J	Keen J	36
aut	Mehlotra RK	Mehlotra RK	37
aut	Baliraine FN	Baliraine FN	38
aut	Baliraine F	Baliraine F	39
aut	Kiwuwa MS	Kiwuwa MS	40
aut	Tukwasibwe S	Tukwasibwe S	41
aut	Conrad	Conrad	42
aut	Nankoberanyi S	Nankoberanyi S	43
aut	Mbogo GW	Mbogo GW	44
aut	Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, Mugyenyi P, Sie A, Wasunna M, Kain KC, DjimdÌ© AA, Sarkar S, Chandra R, Robbins J, Dunne MW	Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, Mugyenyi P, Sie A, Wasunna M, Kain KC, DjimdÌ© AA, Sarkar S, Chandra R, Robbins J, Dunne MW	45
aut	Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ	Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ	46
per	null	:::UNDEF:::
